AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03176056 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calori restricted diet
Description: For the calori restricted diet group, the target total calorie intake was calculated by multiplying the ideal body weight by 25 kcal/kg for those with a BMI in the range 18.5 to 24, 20 kcal/kg for obese subjects with a BMI > 24 and 30 kcal/day for underweight subjects with a BMI \<18.5. The macronutrient percentage was 50-60% for carbohydrate, 1.0-1.2 g/kg for protein and fat ≦30%.
Study NCT03132779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid
Description: Adose of intralipid given and rechecking NKcells activity
Study NCT01693575 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pupil expansion with APX 100 device
Description: Patients with small pupils (\<4.5 mm) that would not dilate pharmacologically or small pupils that develop intraoperatively due to intraoperative floppy iris syndrome (IFIS) will be assigned to APX 100 device intervention during standard phacoemulsification cataract surgery. After creating two standard clear corneal incisions in the horizontal meridians, two APX 100 retractors will be inserted to the anterior chamber of the eye 180 degrees apart with special forceps, one retractor at a time, and will be located on the pupil's border between the iris and the anterior lens capsule. Then, the devices will be released from the forceps and the pupil diameter will expand. The next steps of the surgery will remain unchanged. After the implantation of the intraocular lens (IOL) in the capsular bag the APX 100 retractors will be removed the same way as inserted. The clear corneal incisions will then be closed by hydration.
Study NCT01881776 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ISB
Description: In SISB group; a 5 cm block needle (Stimuplex®A, B Braun Medical, Bethlehem, PA) was inserted in-plane in order to place the needle tip between the upper and middle trunks of the brachial plexus (C5-C6). 20 mL 0.5% ropivacaine was injected through the needle.~For CISB, a 5cm stimulating needle (Contiplex® Tuohy, B. Braun Medical, Bethlehem, PA) was inserted in-plane in order to place the needle tip between the upper and middle trunks of the brachial plexus (C5-C6). A nonstimulating catheter was inserted approximately 3 cm beyond the tip of the needle. 20 mL 0.5% ropivacaine was injected through the catheter.
Study NCT03006458 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon B
Description: toric contact lens
Study NCT03011970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Study NCT03011970 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04442126 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NM21-1480
Description: Trispecific anti-PD-L1/anti-4-1BB/anti-Human Serum Albumin (HSA) single-chain Fv fusion protein
Study NCT03315273 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Test battery to measure the motor imagery ability
Description: Participants will perform 3 different tests to measure the motor imagery ability
Study NCT03315273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test battery to measure the motor imagery ability
Description: Participants will perform 3 different tests to measure the motor imagery ability
Study NCT00597311 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: 1. Short term radiotherapy 5x5 Gy during 5 days~2. Chemoradiotherapy 50 Gy + 5Fu/Lv
Study NCT00530829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zinc
Description: 10 day blister pack of 20 mg zinc disperable tablets, 1 tablet qd for children 6 months to 4 years, 1/2 tablet qd for children 2-5 months
Study NCT00530829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zinc
Description: 10 day blister pack of 20 mg zinc disperable tablets, 1 tablet qd for children 6 months to 4 years, 1/2 tablet qd for children 2-5 months
Study NCT00998751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral masitinib
Description: 7.5 mg/kg/day
Study NCT03985410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX2514
Description: intravenous infusion
Study NCT03985410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: intravenous infusion
Study NCT03985410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: oral tablet
Study NCT02373956 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MELECTIS G
Description: The experimental medical device (MELECTIS G) is an association of selected honey and pharmaceutical grade hyaluronic acid.
Study NCT02373956 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MELECTIS G
Description: The experimental medical device (MELECTIS G) is an association of selected honey and pharmaceutical grade hyaluronic acid.
Study NCT02373956 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Patients will receive usual care according to the current procedures at the Nîmes University Hospital (ICMD010 concerning pressure sore care and SCMD002 concerning referenced anti-pressure sore dressings).
Study NCT00634712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan
Study NCT00634712 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00050531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gleevec
Description: 400 mg orally twice daily.
Study NCT00050531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-alpha interferon (Peg-Intron)
Description: PEG-IFN 0.5 mcg/kg each week subcutaneously.
Study NCT00050531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim (GM-CSF)
Description: 125 mcg/m\^2 three times per week subcutaneously.
Study NCT01844102 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrePex
Description: PrePex is a sterile device for adult male circumcision, consisting of an inner ring, elastic ring, placement ring, and verification thread. Proper sizing is facilitated by a sizing accessory. The elastic ring is loaded on to the placement ring, which is then placed at the base of the penis. The inner ring is placed inside the foreskin. The elastic ring is then deployed around the foreskin, clamping the foreskin against the inner ring. PrePex is manufactured by Circ MedTech Limited, is certified CE - Class IIa in the European Union, and has been approved by the U.S. Food and Drug Administration.
Study NCT03484481 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Oral Nutritional Support; Nutrena
Description: Patients in group 1 and 3 take ONS 200 ml/day twice a day at home. Patients in group 2 and 3 received IDPN administrations. \]. Its infusion was started 30 minutes after initiation of HD via the venous port of the bubble trap on the HD tubing and continued throughout the entire HD procedure at a rate of 150 ml/h for 30 min and consisted of 300 ml for 3 hour.
Study NCT03484481 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Intradialytic Parenteral Nutrition; Kabiven central
Description: Patients in group 2 and 3 received IDPN administrations Its infusion was started 30 minutes after initiation of HD via the venous port of the bubble trap on the HD tubing and continued throughout the entire HD procedure at a rate of 150 ml/h for 30 min and consisted of 300 ml for 3 hour.
Study NCT00005610 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Study NCT02356055 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STOMP (Skill-building through Task-Oriented Motor Practice)
Description: The STOMP intervention is a package including family-centered goals, task-specific training delivered through motor learning and errorless learning principles. It is unique in the use of massed practice (high-dosage) therapy.
Study NCT02356055 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: STOMP (Skill-building through Task-Oriented Motor Practice)
Description: The STOMP intervention is a package including family-centered goals, task-specific training delivered through motor learning and errorless learning principles. It is unique in the use of massed practice (high-dosage) therapy.
Study NCT02193932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG Triggered fMRI using Micro Maglink
Study NCT00861003 — intervention group
Intervention type: DEVICE
Intervention: Medication Event Monitoring System (MEMS)
Description: MEMS is a medication vial cap that electronically records the date and time of bottle opening.
Study NCT02506452 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biovance®
Description: Application of Biovance® for up to 12 weeks or until wound closure, whichever is sooner. Non-active moist wound treatment, debridement as needed, off-loading
Study NCT02506452 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care, Diabetic Foot Ulcers
Description: Non-active moist wound treatment, debridement as needed, off-loading for up to 12 weeks or until wound closure, whichever is sooner
Study NCT03690557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IncentaHealth
Description: IncentaHealth is a comprehensive, behavioral weight management program designed to help individuals initiate and maintain weight loss. Individuals participate in the IncentaHealth program from their homes, receive program information electronically through daily emails and through a smartphone app for the duration of the study, and have the option to receive text messages and speak with health coaches over the telephone. Participants in this study will be enrolled in the IncentaHealth program for 12 months, and will engage with health coaching, tracking of body weight, and are provided a number of resources for healthy living throughout the 12 months.
Study NCT02397707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxilaprevir
Description: 100 mg tablet administered orally
Study NCT02157948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab (CP2)
Description: Denosumab produced by a process referred to as CP2, administered subcutaneously from a prefilled syringe.
Study NCT02157948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab (CP4)
Description: Denosumab produced by a process referred to as CP4, administered subcutaneously from a prefilled syringe.
Study NCT01276275 — intervention group
Intervention type: DRUG
Intervention: Risk of selected safety events
Description: First time users of ticagrelor, clopidogrel and prasugrel, respectively
Study NCT04230941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAAT-G
Description: Memory and Attention Adaptation Training (MAAT) is a cognitive-behavioral therapy (CBT)-based intervention for CRCD. As a CBT-based intervention, MAAT focuses on an individual's psychological response to injury as compared to the biological events triggering CRCD. MAAT is a series of manualized workshops delivered by a psychologist via video-conferencing, supplemented by a participant workbook, which provide instruction and practice with adaptive behavioral coping skills, stress management techniques, and compensation strategies. MAAT-G has been adapted to optimize usability. We are now testing the feasibility of MAAT-G in older cancer survivors with Mild Cognitive Impairment.
Study NCT02736422 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hyperpolarised Xenon
Description: Hyperpolarised gas Magnetic resonance imaging (MRI) (3He and 129Xe) has enabled novel methods of in-vivo functional lung imaging that do not rely on the use of ionising radiation.
Study NCT01077700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-288 Low Dose
Study NCT01077700 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: inactive substance
Study NCT01077700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-288 High Dose
Study NCT03041155 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Muscle respiratory training
Description: Muscle respiratory training during hemodialysis sessions
Study NCT04597866 — intervention group
Intervention type: BEHAVIORAL
Intervention: Multimodal rehabilitation
Description: A combination of exposure in vivo and interventions directly targeting the cortical reorganization for treating CRPS.
Study NCT00390884 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine, Fluzone®
Description: 0.25 mL, Intramuscular
Study NCT04477707 — intervention group
Intervention type: DRUG
Intervention: Finerenone (BAY94-8862)
Description: 10 mg or 20 mg Finerenone tablet to be given orally, once daily, administered in the FIDELIO or FIGARO clinical trial.
Study NCT03104530 — intervention group
Intervention type: OTHER
Intervention: Brown crabmeat
Description: Those exposed to higher levels of cadmium due to habitual consumption of 40 grams or more per week of brown meat from crab
Study NCT02227134 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound
Description: Ultrasound to measure hyo-mental distance, tonsil size and width of the tongue.
Study NCT03593707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin
Study NCT03593707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571
Description: PF-06865571
Study NCT00539331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2171
Description: oral tablet
Study NCT03670121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bronchoscopic Thermal Vapor Ablation (BTVA)
Description: Bronchoscopic vapor delivery to airway segment(s) targeted for treatment
Study NCT03088800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Oral Ibuprofen at 10 mg/kg dose
Study NCT03088800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APAP
Description: Oral APAP at 15mg/kg dose
Study NCT04724265 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: collection of sample of perilymphatic fluid during cochlear implantation
Description: collection of sample of perilymphatic fluid during cochlear implantation and to analyse it with a CMV polymerised-chain-reaction to evaluate the involvement of CMV in hearing loss.
Study NCT00539331 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: intravenous infusion
Study NCT00539331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: intravenous infusion
Study NCT00539331 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: intravenous injection
Study NCT00539331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: intravenous injection
Study NCT03470818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preparatory instructional videos (flipped classroom model)
Description: The intervention consists in the provision of preparatory instruction about the medical knowledge required to complete the task work of the upcoming simulated acute care clinical situation. The format used to convey this off-loaded educational content will be short (approximately 15 minutes) narrated video PowerPoint presentations; every relevant medical situation incorporated in the simulation case will have a dedicated video presentation.~These videos will be available to the intervention group participants on a web-based platform one week prior to the simulation session
Study NCT03470818 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham video
Description: Participants in the control group will be called to watch an online video prior to the simulation activity. However, this video presentation will not have any form of information regarding the upcoming simulation case; it will be an introductory video discussing the capacities of the simulation facility. This will limit any unwanted snowball effect where discussion between research participants could lead the control group participants to inquire about a video presentation that they would not exposed to.
Study NCT03163615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tibet Rhodiola Capsule
Description: 4 capsules, po, from admission up to 84 days
Study NCT03163615 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: 4 capsules, po, from admission up to 84 days
Study NCT03210376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep Neuromuscular Blockade (NMB)
Description: Deep Neuromuscular Blockade (NMB) given during surgery.
Study NCT03210376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moderate Neuromuscular Blockade (NMB)
Description: Moderate Neuromuscular Blockade (NMB) given during surgery.
Study NCT04376775 — intervention group
Intervention type: OTHER
Intervention: Transplant patient
Description: Surveys will be distributed via an email sent by transplant centres or patient's associations. A link to a secure survey platform will be given. A questionnaire will completed by patients. Patients, who agreed to fill the survey, will be offered the possibility to be contacted for a second survey over a 6 months period.
Study NCT06607471 — intervention group
Intervention type: OTHER
Intervention: Support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablation
Description: Treatment will be patient-tailored, integrating international guidelines recommendation and the experience of the center where enrollment takes place.
Study NCT06607471 — intervention group
Intervention type: OTHER
Intervention: Support treatment, cardiac medical treatment, aetiology-specific treatment
Description: Treatment will be patient-tailored, integrating international guidelines recommendation and the experience of the center where enrollment takes place.
Study NCT02983266 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: InTENsity MicroCombo
Description: An electrotherapy device.
Study NCT02983266 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InTENsity MicroCombo
Description: An electrotherapy device.
Study NCT02983266 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: InTENsity MicroCombo
Description: An electrotherapy device.
Study NCT02089295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 5 mg PF-00345439 Formulation K, single dose, under fed conditions
Study NCT02089295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 20 mg PF-00345439 Formulation K, single dose, under fed conditions
Study NCT02089295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 40 mg PF-00345439 Formulation K, single dose, under fed conditions
Study NCT02186106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Study NCT02525822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-123 Lotion
Description: Investigational Product: IDP-123 Lotion
Study NCT03210376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: 4 mg/Kg, intravenously as a single bolus injection after surgery.
Study NCT03210376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine
Description: 70 mcg/Kg up to a total of 5 mg, intravenously slowly over a period of at least 1 minute after surgery.
Study NCT02525822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazorac Cream, 0.1%,
Description: Comparator Product: Tazorac Cream, 0.1%
Study NCT02525822 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Comparator Product: Vehicle Cream
Study NCT02525822 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Lotion
Description: Comparator Product: Vehicle Lotion
Study NCT03363945 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MDR-101
Description: Enriched CD34+ hematopoietic stem cells and defined dose of CD3+ T-cells
Study NCT02972424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide Prefilled Syringe
Description: TPTD 20 mcg
Study NCT02972424 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo as a prefilled syringe with all inactive ingredients
Study NCT01141075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: Ataluren will be provided as a vanilla-flavored powder to be mixed with water.
Study NCT03069209 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cells
Description: Intraovarian transplantation of autologous purified bone marrow-derived stem cells and mesenchymal stem cells.
Study NCT03476772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalbuphine
Description: Children will be randomly assigned into 2 groups of 30 patients each. They will receive caudal anesthesia using bupivacaine 0.25% 1ml/kg plus 2 ml normal saline in the control group, bupivacaine 0.25% 1ml/kg plus nalbuphine 0.1 mg/kg in 2 ml solution in the nalbuphine group.
Study NCT03292692 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OurRelationship
Description: Online intervention with coach support
Study NCT01800305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated rhEPO
Study NCT01800305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPIAO®
Study NCT01448109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Hydrocortisone 100mg vial (blinded) is reconstituted with 2ml of water for Injection, agitated for 20 seconds, rested for 3 minutes, contents of vial aspirated and added to 100ml bag of normal saline or 5% dextrose and given intravenously as a continuous infusion at rate of 200mg/per day for 7 days.